When Acid Reflux Increases… Choose Advanced Dual Therapy
The Most Advanced PPI for Acid Regulation
EraZole-D 40 Summary Table
| Parameter | Details |
|---|---|
| Brand name | EraZole-D 40 |
| Composition | Esomeprazole 40 mg (EC) + Domperidone 30 mg (SR) |
| Dosage form | Capsule |
| Therapeutic class | Proton pump inhibitor + Prokinetic agent |
| Mechanism of action | Esomeprazole reduces gastric acid secretion; Domperidone enhances gastric motility and emptying |
| Indications | GERD, NERD, functional dyspepsia, acid reflux |
| Recommended dose | 1 capsule daily before meals |
| Common side effects | Headache, nausea, constipation, abdominal discomfort |
| Precautions | Monitor long-term PPI use; caution in liver disease and cardiac patients |
| Storage | Store below 30°C, dry and protected from light |
| Key advantages | Dual-action therapy, long-lasting relief, improved gastric motility |
Product Summary
EraZole-D 40 is a combination of Esomeprazole 40 mg (enteric-coated) and Domperidone 30 mg (sustained release) designed for effective management of acid reflux disorders and gastrointestinal motility disturbances.
This dual-action therapy reduces gastric acid secretion while improving gastrointestinal motility, providing comprehensive and long-lasting relief from acidity, heartburn, and reflux-related symptoms.
Esomeprazole, a next-generation proton pump inhibitor (PPI), promotes healing of erosive esophagitis and offers superior acid control, while Domperidone enhances gastric emptying and reduces nausea and bloating.
Key Benefits
➤ Advanced Acid Suppression
- Esomeprazole provides potent and sustained inhibition of gastric acid secretion
- Helps heal erosive GERD and protects the esophageal lining
- Demonstrated superior maintenance of healing compared to older PPIs like lansoprazole or pantoprazole
➤ Improved Gastrointestinal Motility
- Domperidone regulates gastric and intestinal smooth muscle activity
- Enhances gastric emptying and reduces bloating and discomfort
➤ Dual Action for Complete Relief
- Combines acid suppression + prokinetic action
- Provides relief from heartburn, regurgitation, nausea, and dyspepsia
- Improves overall digestive comfort and quality of life
Mechanism of Action
Esomeprazole (40 mg)
- Proton pump inhibitor (PPI)
- Irreversibly blocks H⁺/K⁺-ATPase enzyme in gastric parietal cells
- Reduces gastric acid secretion and promotes mucosal healing
Domperidone (30 mg SR)
- Dopamine (D₂) receptor antagonist
- Enhances gastric motility and emptying
- Reduces reflux episodes and relieves nausea
Indications
EraZole-D 40 is indicated for:
- Gastroesophageal Reflux Disease (GERD)
- Non-erosive reflux disease (NERD)
- Functional dyspepsia
- Acid reflux with delayed gastric emptying
- Heartburn, bloating, and regurgitation
Dosage & Administration
- One capsule daily, preferably before meals
- Swallow whole; do not crush or chew
- Use as directed by physician
Side Effects
Generally mild and transient:
- Headache
- Diarrhea or constipation
- Nausea
- Abdominal discomfort
- Dry mouth
Precautions
- Use cautiously in patients with liver impairment
- Domperidone should be used carefully in patients with cardiac risk factors
- Long-term PPI use should be monitored (Vitamin B12, magnesium levels)
- Not recommended during pregnancy unless prescribed
Storage
Store below 30°C, in a cool, dry place, protected from moisture and sunlight.
Key Advantages of EraZole-D 40
- Dual therapy: PPI + Prokinetic
- Superior acid control and esophageal protection
- Improves gastric motility and digestion
- Once-daily sustained relief
- Effective in both GERD and dyspepsia
References (APA 7)
Kahrilas, P. J., Shaheen, N. J., Vaezi, M. F., & American Gastroenterological Association. (2008). American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology, 135(4), 1383–1391. https://doi.org/10.1053/j.gastro.2008.08.045
Sharma, P., & Vakil, N. (2011). Review article: Acid suppression and proton pump inhibitors in gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 34(2), 123–136. https://doi.org/10.1111/j.1365-2036.2011.04707.x
Moayyedi, P., & Delaney, B. (2010). Gastro-oesophageal reflux disease. The Lancet, 375(9713), 119–128. https://doi.org/10.1016/S0140-6736(09)60691-0
Vial, T., & Descotes, J. (1997). Clinical toxicity of domperidone. Drug Safety, 17(6), 433–448. https://doi.org/10.2165/00002018-199717060-00004
Forgacs, I., & Loganayagam, A. (2008). Overprescribing proton pump inhibitors. BMJ, 336(7634), 2–3. https://doi.org/10.1136/bmj.39406.449456.BE